PL2115477T3 - Zastosowanie IGFBP-7 do oceny niewydolności serca - Google Patents

Zastosowanie IGFBP-7 do oceny niewydolności serca

Info

Publication number
PL2115477T3
PL2115477T3 PL08707286T PL08707286T PL2115477T3 PL 2115477 T3 PL2115477 T3 PL 2115477T3 PL 08707286 T PL08707286 T PL 08707286T PL 08707286 T PL08707286 T PL 08707286T PL 2115477 T3 PL2115477 T3 PL 2115477T3
Authority
PL
Poland
Prior art keywords
igfbp
assessment
heart failure
heart
failure
Prior art date
Application number
PL08707286T
Other languages
English (en)
Inventor
Ursula-Henrike Wienhues-Thelen
Dirk Block
Andrew Emili
Vincent Fong
Anthony Gramolini
Georg Hess
Hendrik Huedig
Ruth Isserlin
Thomas Kislinger
Peter Liu
David Maclennan
Der Eltz Herbert Von
Original Assignee
Hoffmann La Roche
Governing Council Univ Toronto
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche, Governing Council Univ Toronto filed Critical Hoffmann La Roche
Publication of PL2115477T3 publication Critical patent/PL2115477T3/pl

Links

Classifications

    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47Assays involving proteins of known structure or function as defined in the subgroups
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47Assays involving proteins of known structure or function as defined in the subgroups
    • G01N2333/4701Details
    • G01N2333/4727Calcium binding proteins, e.g. calmodulin
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47Assays involving proteins of known structure or function as defined in the subgroups
    • G01N2333/4701Details
    • G01N2333/4737C-reactive protein
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47Assays involving proteins of known structure or function as defined in the subgroups
    • G01N2333/4701Details
    • G01N2333/4745Insulin-like growth factor binding protein
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/52Assays involving cytokines
    • G01N2333/54Interleukins [IL]
    • G01N2333/5412IL-6
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/575Hormones
    • G01N2333/58Atrial natriuretic factor complex; Atriopeptin; Atrial natriuretic peptide [ANP]; Brain natriuretic peptide [BNP, proBNP]; Cardionatrin; Cardiodilatin
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00Detection or diagnosis of diseases
    • G01N2800/32Cardiovascular disorders
    • G01N2800/325Heart failure or cardiac arrest, e.g. cardiomyopathy, congestive heart failure
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00Detection or diagnosis of diseases
    • G01N2800/56Staging of a disease; Further complications associated with the disease

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Immunology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
PL08707286T 2007-01-25 2008-01-25 Zastosowanie IGFBP-7 do oceny niewydolności serca PL2115477T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP07001582 2007-01-25
EP08707286.4A EP2115477B1 (en) 2007-01-25 2008-01-25 Use of igfbp-7 in the assessment of heart failure
PCT/EP2008/000576 WO2008089994A1 (en) 2007-01-25 2008-01-25 Use of igfbp-7 in the assessment of heart failure

Publications (1)

Publication Number Publication Date
PL2115477T3 true PL2115477T3 (pl) 2015-12-31

Family

ID=37810309

Family Applications (1)

Application Number Title Priority Date Filing Date
PL08707286T PL2115477T3 (pl) 2007-01-25 2008-01-25 Zastosowanie IGFBP-7 do oceny niewydolności serca

Country Status (10)

Country Link
US (4) US20100285491A1 (pl)
EP (2) EP2498095A3 (pl)
JP (1) JP2010517023A (pl)
CN (2) CN101636656A (pl)
CA (1) CA2671298C (pl)
DK (1) DK2115477T3 (pl)
ES (1) ES2548009T3 (pl)
HU (1) HUE025408T2 (pl)
PL (1) PL2115477T3 (pl)
WO (1) WO2008089994A1 (pl)

Families Citing this family (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2010517023A (ja) * 2007-01-25 2010-05-20 エフ.ホフマン−ラ ロシュ アーゲー 心不全の評価におけるigfbp−7の使用
WO2010096713A2 (en) * 2009-02-20 2010-08-26 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Method for the diagnosis of age-associated vascular disorders
ES2512018T3 (es) * 2009-07-27 2014-10-23 F. Hoffmann-La Roche Ag Utilización de mimecán en la evaluación de la insuficiencia cardiaca
EP3151005A1 (en) * 2009-08-28 2017-04-05 Astute Medical, Inc. Methods for diagnosis of renal injury and renal failure
US10830773B2 (en) 2009-12-20 2020-11-10 Astute Medical, Inc. Methods for prognosis of future acute renal injury and acute renal failure
HUE029304T2 (en) * 2010-02-05 2017-02-28 Astute Medical Inc Procedures and Preparations for Diagnosing and Predicting Kidney Damage and Kidney Failure
CN105044349B (zh) * 2010-08-26 2018-04-06 弗·哈夫曼-拉罗切有限公司 生物标志物在评估从动脉高血压向心力衰竭的早期转变中的用途
FI20115367A0 (fi) * 2011-04-15 2011-04-15 Hytest Oy Menetelmä sydän- ja verisuonitapahtumien määrittämiseksi käyttämällä IGFBP-fragmentteja
WO2013053076A1 (en) * 2011-10-10 2013-04-18 Zensun (Shanghai)Science & Technology Limited Compositions and methods for treating heart failure
EP2769227B1 (en) 2011-10-17 2016-07-27 Roche Diagnostics GmbH Troponin and bnp based diagnosis of risk patients and cause of stroke
ES2933570T3 (es) 2011-12-08 2023-02-10 Astute Medical Inc Métodos y composiciones para el diagnóstico y el pronóstico de una lesión renal y de una insuficiencia renal
LT2883057T (lt) 2012-08-09 2019-04-25 Institut National De La Santé Et De La Recherche Médicale (Inserm) Širdies nepakankamumo diagnostika
CA2883890C (en) * 2012-09-12 2021-11-09 Dirk Block Identification of patients with abnormal fractional shortening
EP2730923A1 (en) * 2012-11-09 2014-05-14 Roche Diagniostics GmbH NTproBNP and cTnT based therapy guidance in heart failure
CN113759128A (zh) * 2012-12-04 2021-12-07 霍夫曼-拉罗奇有限公司 心力衰竭疗法的选择中的生物标记物
AU2014207509B2 (en) 2013-01-17 2019-12-12 Astute Medical, Inc. Methods and compositions for diagnosis and prognosis of renal injury and renal failure
SMT201900258T1 (it) 2013-06-06 2019-07-11 Inst Nat Sante Rech Med Biomarcatore di re-ospedalizzazione dopo scompenso cardiaco
EP3441768A3 (en) * 2013-08-26 2019-03-20 Roche Diagnostics GmbH Marker for statin treatment stratification in heart failure
CA2929547C (en) * 2013-11-06 2023-02-28 Astute Medical, Inc. Assays for igfbp7 having improved performance in biological samples
US10300108B2 (en) 2013-12-03 2019-05-28 Astute Medical, Inc. Methods and compositions for diagnosis and prognosis of renal injury and renal failure
CN104758922A (zh) 2014-01-03 2015-07-08 上海泽生科技开发有限公司 纽兰格林制剂的配方
ES2712201T3 (es) 2014-01-28 2019-05-09 Hoffmann La Roche Biomarcadores para la evaluación de riesgos y la monitorización del tratamiento en pacientes de insuficiencia cardíaca que han recibido terapia guiada por el péptido natriurético de tipo B
EP2924438B1 (en) 2014-03-26 2018-04-18 Roche Diagnostics GmbH IGFBP7 for diagnosing diastolic dysfunction
CN103926401A (zh) * 2014-03-31 2014-07-16 瑞莱生物科技(江苏)有限公司 一种快速定量检测igfbp-7和timp-2的免疫荧光试纸条及其制备方法
CN105561298A (zh) 2014-10-17 2016-05-11 上海泽生科技开发有限公司 神经调节蛋白用于预防、治疗或延迟射血分数保留的心力衰竭的方法和组合物
WO2016066698A1 (en) * 2014-10-29 2016-05-06 Roche Diagnostics Gmbh Biomarkers for risk prediction of mortality
CN104408717A (zh) * 2014-11-24 2015-03-11 北京航空航天大学 一种基于着色分离的病理图像颜色质量综合评价方法
US11243202B2 (en) 2015-04-09 2022-02-08 Astute Medical, Inc. Methods and compositions for diagnosis and prognosis of renal injury and renal failure
JP7080176B2 (ja) 2016-02-29 2022-06-03 エフ.ホフマン-ラ ロシュ アーゲー 子癇前症におけるマーカーとしてのigfbp-7
AU2017277305A1 (en) 2016-06-06 2018-12-20 Astute Medical, Inc. Management of acute kidney injury using insulin-like growth factor-binding protein 7 and tissue inhibitor of metalloproteinase 2
BR112018073214A2 (pt) 2016-06-17 2019-04-16 F. Hoffmann-La Roche Ag métodos para a previsão do risco de recorrência da fibrilação atrial, para o diagnóstico de fibrilação atrial em um indivíduo, para o monitoramento de uma terapia e para a classificação da fibrilação e utilizações do biomarcador
US10865412B2 (en) * 2016-11-04 2020-12-15 Ottawa Heart Institute Research Therapeutics targeting IGFBP7 for the treatment or prevention of heart failure and metabolic diseases
EP3724662B1 (en) 2017-12-13 2024-02-28 Roche Diagnostics GmbH Circulating angiopoietin-2 (ang-2) and insulin-like growth factor-binding protein 7 (igfbp7) for the prediction of stroke
WO2020016441A1 (en) 2018-07-20 2020-01-23 Roche Diagnostics Gmbh Prediction of preeclampsia based on igfbp-7
BR112021002445A2 (pt) 2018-08-10 2021-05-04 F. Hoffmann-La Roche Ag métodos para prever o risco de acidente vascular cerebral, para aprimorar a precisão da previsão de uma pontuação de risco clínico, para avaliar a eficácia de uma terapia, para identificar um paciente e para monitorar um paciente, usos e kit
CN113302497B (zh) 2018-08-16 2024-10-18 豪夫迈·罗氏有限公司 循环tfpi-2(组织因子途径抑制剂2)在心房颤动和抗凝治疗评定中的应用
WO2020039001A1 (en) 2018-08-22 2020-02-27 Roche Diagnostics Gmbh Circulating spon-1 (spondin-1) in the assessment of atrial fibrillation
KR20210049829A (ko) 2018-08-24 2021-05-06 에프. 호프만-라 로슈 아게 심방 세동의 사정에서 및 뇌졸중의 예측을 위한 순환하는 fgfbp-1 (섬유모세포 성장 인자-결합 단백질 1)
US11931207B2 (en) 2018-12-11 2024-03-19 Eko.Ai Pte. Ltd. Artificial intelligence (AI) recognition of echocardiogram images to enhance a mobile ultrasound device
US12400762B2 (en) 2018-12-11 2025-08-26 Eko.Ai Pte. Ltd. Automatic clinical workflow that recognizes and analyzes 2D and doppler modality echocardiogram images for automated cardiac measurements and diagnosis of cardiac amyloidosis and hypertrophic cardiomyopathy
US12001939B2 (en) 2018-12-11 2024-06-04 Eko.Ai Pte. Ltd. Artificial intelligence (AI)-based guidance for an ultrasound device to improve capture of echo image views
US12322100B2 (en) 2018-12-11 2025-06-03 Eko.Ai Pte. Ltd. Automatic clinical workflow that recognizes and analyzes 2D and doppler modality echocardiogram images for automated cardiac measurements and grading of aortic stenosis severity
US11446009B2 (en) 2018-12-11 2022-09-20 Eko.Ai Pte. Ltd. Clinical workflow to diagnose heart disease based on cardiac biomarker measurements and AI recognition of 2D and doppler modality echocardiogram images
EP3951387A4 (en) * 2019-03-29 2022-11-23 Eiken Kagaku Kabushiki Kaisha MARKER FOR ARTERIOSCLEROSIS AND ARTERIOSCLEROSIS-RELATED DISEASE
CN113939741B (zh) 2019-05-23 2025-07-22 豪夫迈·罗氏有限公司 HFpEF的IGFBP7比率
EP4196796A1 (en) 2020-08-14 2023-06-21 F. Hoffmann-La Roche AG Igfbp7 for the assessment of silent brain infarcts and cognitive decline
CN115957301A (zh) * 2021-10-13 2023-04-14 中国科学院上海营养与健康研究所 一种促进心梗心肌修复的细胞分泌因子及应用
CN118871785A (zh) 2022-03-18 2024-10-29 豪夫迈·罗氏有限公司 用于2型与1型急性心肌梗死的早期辨别的肌钙蛋白标志物组合

Family Cites Families (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US686A (en) 1838-04-13 Machine foe faking- and goring
US6174A (en) 1849-03-13 Improvement in balances for weighing
DE3922873A1 (de) 1989-04-25 1990-10-31 Boehringer Mannheim Gmbh Spezifische antikoerper gegen troponin t, ihre herstellung und verwendung in einem reagenz zur bestimmung von hermuskelnekrosen
US6333397B1 (en) 1989-04-25 2001-12-25 Roche Diagnostics Gmbh Monoclonal antibodies to troponin T and their production
JPH07132095A (ja) 1993-06-11 1995-05-23 Nawata Arata Dnaおよびそのコードする蛋白質
US5807522A (en) 1994-06-17 1998-09-15 The Board Of Trustees Of The Leland Stanford Junior University Methods for fabricating microarrays of biological samples
US6174686B1 (en) * 1995-04-18 2001-01-16 Biosite Diagnostics, Inc. Methods for the assay of troponin I and T and complexes of troponin I and T and selection of antibodies for use in immunoassays
EP1151101A4 (en) 1998-12-18 2002-10-09 Human Genome Sciences Inc PROSTACYCLINE STIMULANT FACTOR-2
WO2000035473A2 (en) * 1998-12-18 2000-06-22 Scios Inc. Methods for detection and use of differentially expressed genes in disease states
US6709855B1 (en) 1998-12-18 2004-03-23 Scios, Inc. Methods for detection and use of differentially expressed genes in disease states
PT1141014E (pt) * 1999-01-06 2005-04-29 Genentech Inc Variante mutante do factor de crescimento semelhante a insulina (igf-i)
ES2292426T3 (es) * 1999-01-29 2008-03-16 Roche Diagnostics Gmbh Metodo para detectar probnp n-terminal.
US7071160B2 (en) 2000-06-15 2006-07-04 Kyowa Hakko Kogyo Co., Ltd. Insulin-like growth factor-binding protein
US20030119009A1 (en) * 2001-02-23 2003-06-26 Stuart Susan G. Genes regulated by MYCN activation
US7713705B2 (en) * 2002-12-24 2010-05-11 Biosite, Inc. Markers for differential diagnosis and methods of use thereof
US7632647B2 (en) * 2001-04-13 2009-12-15 Biosite Incorporated Use of B-type natriuretic peptide as a prognostic indicator in acute coronary syndromes
ATE458199T1 (de) * 2001-05-04 2010-03-15 Biosite Inc Diagnostische marker der akuten koronaren syndrome und ihre verwendungen
GB0130557D0 (en) 2001-12-20 2002-02-06 Serono Internat S A Proteins
AU2003301843A1 (en) 2002-05-17 2004-06-07 Human Genome Sciences, Inc. 157 human secreted proteins
GB0216191D0 (en) * 2002-07-11 2002-08-21 Univ Leicester Plasma urotensin in human heart failure
CA2522378C (en) 2003-05-12 2011-03-29 Volker Klemt Method of detecting probnp with a monoclonal antibody binding to the amino acids 41-46
GB0329288D0 (en) * 2003-12-18 2004-01-21 Inverness Medical Switzerland Monitoring method and apparatus
US20060003338A1 (en) 2004-06-30 2006-01-05 Deng David X System and methods for the management and treatment of vascular graft disease
US7659091B2 (en) * 2004-09-21 2010-02-09 Nourheart, Inc. Diagnostic marker
ITVI20050059A1 (it) 2005-03-04 2006-09-05 Consorzio Per Gli Studi Universitari In Verona Nuovi biomarcatori per la diagnosi e/o la prognosi di neoplasie in animali
EP1875248A2 (en) * 2005-03-29 2008-01-09 Inverness Medical Switzerland GmbH Device and method of monitoring a patient
DE102005014752A1 (de) * 2005-03-31 2006-11-23 Johannes-Gutenberg-Universität Mainz Entzündungsmarker und Kombinationen davon als biochemische Marker bei kardiovaskulären Erkrankungen
EP1722232A1 (en) * 2005-05-09 2006-11-15 F.Hoffmann-La Roche Ag Devices and methods for diagnosing or predicting early stage cardiac dysfunctions
EP1731910A1 (en) * 2005-06-07 2006-12-13 F. Hoffmann-La Roche Ag Use of NT-proANP and NT-proBNP for diagnosing cardiac diseases
US7842472B2 (en) * 2006-11-14 2010-11-30 Alere International Methods and compositions for monitoring and risk prediction in cardiorenal syndrome
JP2010517023A (ja) * 2007-01-25 2010-05-20 エフ.ホフマン−ラ ロシュ アーゲー 心不全の評価におけるigfbp−7の使用
ES2339284T3 (es) * 2007-03-06 2010-05-18 F. Hoffmann-La Roche Ag Utilizacion de nogo-c en la deteccion de la insufuciencia cardiaca.
ES2440740T3 (es) * 2007-03-08 2014-01-30 F. Hoffmann-La Roche Ag Utilización de SLIM-1 en la evaluación de la insuficiencia cardiaca
ES2512018T3 (es) * 2009-07-27 2014-10-23 F. Hoffmann-La Roche Ag Utilización de mimecán en la evaluación de la insuficiencia cardiaca

Also Published As

Publication number Publication date
EP2115477A1 (en) 2009-11-11
US10996229B2 (en) 2021-05-04
US10488422B2 (en) 2019-11-26
CA2671298C (en) 2020-07-28
US20100285491A1 (en) 2010-11-11
CN101636656A (zh) 2010-01-27
WO2008089994A8 (en) 2009-05-22
US20200064359A1 (en) 2020-02-27
EP2498095A2 (en) 2012-09-12
CA2671298A1 (en) 2008-07-31
HUE025408T2 (hu) 2016-02-29
US20150293122A1 (en) 2015-10-15
DK2115477T3 (en) 2015-08-10
CN106908603B (zh) 2019-04-02
EP2498095A3 (en) 2012-11-28
ES2548009T3 (es) 2015-10-13
US20170016918A1 (en) 2017-01-19
EP2115477B1 (en) 2015-06-24
WO2008089994A1 (en) 2008-07-31
JP2010517023A (ja) 2010-05-20
CN106908603A (zh) 2017-06-30

Similar Documents

Publication Publication Date Title
PL2115477T3 (pl) Zastosowanie IGFBP-7 do oceny niewydolności serca
ZA201007523B (en) Heart age assessment
IL212451A0 (en) Adsorptive structures and the use thereof
IL191773A0 (en) Cardiac mechanical assessment using ultrasound
GB0701426D0 (en) Compounds and their use
GB0803018D0 (en) Therapeutic compounds and their use
GB0818241D0 (en) Compounds and their use
PL2036882T3 (pl) Związki o jonach obojnaczych i ich zastosowanie
SI2344449T1 (sl) Aril-fenil-sulfonamido-cikloalkilne spojine in njihova uporaba
IL208081A0 (en) Amido - thiophene compounds and their use
GB0817208D0 (en) Therapeutic apsap compounds and their use
ZA201007395B (en) Aryl-quinolyl compounds and their use
EP2307052A4 (en) ANTI-BETA-2-MICROGLOBULIN AGENTS AND THEIR USE
SI2496415T1 (sl) Enostransko matirane folije in njihova uporaba
IL212672A (en) Cycloandesdepsipeptide compounds and their use in drug production
GB0812913D0 (en) Therapeutic compounds and their use
GB0708507D0 (en) Substituted phosphonates and their use
HU0700180V0 (en) Loading area of the mattresses
EP2252305A4 (en) OMENTUM AND ITS USE
EP2363132A4 (en) USE OF SOPHORICOSIDE IN DRUG MANUFACTURE
PT2182954T (pt) Utilização de ácidos nor-biliares no tratamento de arteriosclerose
GB0801319D0 (en) Compounds and their use
GB0703514D0 (en) Use of riboflavin
PL393311A1 (pl) Elektroda wielowarstwowa i jej zastosowanie
GB0802128D0 (en) Therapeutic compounds and their use